Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 8 | 2022 | 624 | 1.450 |
Why?
|
| Head and Neck Neoplasms | 7 | 2022 | 561 | 1.060 |
Why?
|
| Quinolines | 1 | 2020 | 48 | 0.730 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 163 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2022 | 444 | 0.660 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2022 | 92 | 0.660 |
Why?
|
| Human papillomavirus 16 | 2 | 2015 | 19 | 0.630 |
Why?
|
| Sulfones | 1 | 2015 | 45 | 0.520 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 55 | 0.500 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 49 | 0.480 |
Why?
|
| Pyrimidines | 1 | 2015 | 178 | 0.470 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 307 | 0.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 300 | 0.410 |
Why?
|
| Chemoradiotherapy, Adjuvant | 3 | 2021 | 33 | 0.360 |
Why?
|
| Mouth Neoplasms | 2 | 2021 | 206 | 0.300 |
Why?
|
| Lung Neoplasms | 1 | 2015 | 1172 | 0.280 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 13 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 151 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Cyclopropanes | 1 | 2020 | 10 | 0.190 |
Why?
|
| Cetuximab | 1 | 2020 | 19 | 0.190 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 35 | 0.190 |
Why?
|
| Premedication | 1 | 2020 | 49 | 0.180 |
Why?
|
| Sulfides | 1 | 2020 | 43 | 0.180 |
Why?
|
| Survival Analysis | 2 | 2021 | 714 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 125 | 0.180 |
Why?
|
| Acetates | 1 | 2020 | 74 | 0.180 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 68 | 0.170 |
Why?
|
| Humans | 16 | 2022 | 68549 | 0.170 |
Why?
|
| Aged | 9 | 2022 | 14842 | 0.160 |
Why?
|
| Travel | 1 | 2018 | 38 | 0.160 |
Why?
|
| Aged, 80 and over | 5 | 2022 | 4843 | 0.160 |
Why?
|
| Middle Aged | 10 | 2022 | 21119 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 87 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 375 | 0.150 |
Why?
|
| Gene Rearrangement | 1 | 2015 | 19 | 0.130 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7268 | 0.130 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 75 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 100 | 0.130 |
Why?
|
| Treatment Failure | 1 | 2015 | 216 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 508 | 0.120 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 799 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 332 | 0.110 |
Why?
|
| Survival Rate | 3 | 2021 | 1055 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 331 | 0.110 |
Why?
|
| Male | 9 | 2022 | 37283 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 104 | 0.100 |
Why?
|
| Female | 8 | 2022 | 38021 | 0.090 |
Why?
|
| Adult | 5 | 2022 | 21379 | 0.080 |
Why?
|
| Risk Factors | 2 | 2017 | 5720 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 3256 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 951 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1070 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 791 | 0.070 |
Why?
|
| Smoking | 1 | 2015 | 1449 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2021 | 7028 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2022 | 129 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 87 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 15 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 192 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 66 | 0.050 |
Why?
|
| Neck Dissection | 1 | 2021 | 55 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2020 | 274 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2021 | 383 | 0.040 |
Why?
|
| Animals | 1 | 2015 | 20880 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2020 | 621 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| United States | 2 | 2021 | 7338 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 445 | 0.030 |
Why?
|
| Threonine | 1 | 2015 | 47 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2018 | 322 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 730 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3703 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 772 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2015 | 1200 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 5710 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 8904 | 0.020 |
Why?
|